ClinicalTrials.gg
RecruitingNCT00091871Updated Oct 29, 2026

A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression

An observational study in Eosinophilia and Hypereosinophilic Syndrome, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Recruiting at 1 site in United States. Open to participants aged 1 Year to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Primary conditionHypereosinophilic SyndromeRegistry: EosinophiliaReclassifiedWhy we changed it
Registry
Eosinophilia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypereosinophilic Syndrome
Why
  1. The study's listed conditions name Hypereosinophilic Syndrome, a narrower term within Eosinophilia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Observational

How we know

From the registry’s dates

  • Started Jun 2005; still recruiting 21 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Family-based
Time perspective
Prospective
Enrollment
50
Ages
1 Year to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Hypereosinophilic Syndrome with a site in United States — 3 open to participants now, 8 under way, 3 of them phase 3. Hypereosinophilic Syndrome · United States.

Started
2005
with 2 others
Observational
2 of 23
1 open now
Registered
5th of 23
by date
Lead sponsor
5 of 23
National Institute of Allergy and Infectious Diseases (NIAID)

Among the 23 studies in Hypereosinophilic Syndrome with a site in United States, this one is one of 3 that started in 2005, is one of 2 observational ones, and was the 5th registered.

Hypereosinophilic Syndrome

40 studies on the registry are indexed under Hypereosinophilic Syndrome; 8 are open to participants now.

Browse Hypereosinophilic Syndrome studies →

Open to participants now

3 of the 23 studies in Hypereosinophilic Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Hypereosinophilic Syndrome studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 1 Year to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Hypereosinophilic Syndrome with a site in United States, or all of them as a file.
02

Study summary

Eosinophils are a type of white blood cell. Elevated eosinophil levels can damage the heart, nerves, and other organs, in the syndrome known as hypereosinophilic syndrome (HES). Some individuals have a hereditary form of HES known as familial eosinophilia (FE). More research on the causation and mechanisms of HES is needed in order to design more effective and less toxic therapies.

This study will investigate FE and its genetic causes, damage mechanisms, and disease markers (such as blood test abnormalities). It will enroll approximately 50 individuals (both adults and children) from a previously studied family with FE. This is a long-term study of indefinite duration.

Participants will undergo yearly clinical examinations including medical history, physical examination, bloodwork, EKG, echocardiogram, and pulmonary function tests, with additional or more frequent examinations and tests as required. In addition, participants will donate blood and tissue for research purposes. Both adult and child participants will donate blood. At the initial evaluation, adult participants will donate bone marrow. During the study, some adult participants will also undergo a limited number of leukaopheresis sessions, in which blood is donated from one arm, the blood is separated into red blood cells and other components, and the red blood cells are returned into the donor's other arm.

Read the detailed description

Study Description:

Affected and unaffected members of families with familial hypereosinophilia (FE) will be enrolled and evaluated on this protocol. For affected family members, a thorough clinical evaluation will be performed with emphasis on potential sequelae of eosinophil-mediated tissue damage. Blood cells, bone marrow and/or serum will also be collected to provide reagents (such as DNA, RNA, and specific antibodies) for use in the laboratory to address issues related to the genetic and immunologic basis of FE as well as its pathogenesis. It is anticipated that affected family members will undergo a more extensive evaluation than is generally available and that the specimens collected from them will prove to be valuable reagents for laboratory studies related to eosinophilia, eosinophil activation and function. While the study is not designed to address the question of therapy for FE, in patients for whom medical therapy is indicated (for either the hypereosinophilia itself or its sequelae), appropriate treatment will be instituted by our clinical service or the patients local physicians. No experimental chemotherapy is involved in this protocol. Unaffected family members will provide research specimens on this protocol to help determine the underlying genetic causes of FE.

Objectives:

Primary Objective: To study the natural history of familial hypereosinophilia (FE)

Secondary Objectives:

  1. To determine the immunologic and molecular mechanisms responsible for eosinophilia, eosinophil activation, and pathogenesis in FE
  2. To identify early clinical or laboratory markers of disease progression

Endpoints: Primary Endpoint: Development of eosinophilic end organ manifestations

Secondary Endpoints:

1a. Description of immunologic features of FE.

1b. Identification of genetic driver(s) of FE

2. Identification of clinical or laboratory markers that become abnormal prior to disease progression in FE

03

Conditions studied

  • Eosinophilia
  • Hypereosinophilic Syndrome

Browse trials for

Keywords

  • Hypereosinophilia
  • Eosinophil
  • Familial
  • Interleukin 5
  • Natural History
  • Familial Hypereosinophilia
  • FE
04

In context

Hypereosinophilic Syndrome Reclassified

40 studies on the registry are indexed under Hypereosinophilic Syndrome; 8 are open to participants now.

Browse Hypereosinophilic Syndrome studies →

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,449 studies on the registry; 181 are open to participants now.

Of its 406 completed or terminated interventional studies of FDA-regulated products, 303 (75%) have results posted.

Compared within Hypereosinophilic Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Eosinophilia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
1 Year to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Affected family members from the previously identified family with FE, as well as affected member of newly identified families with FE and unaffected family members from known families with FE, may enroll.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 1-100 years of age
  • Genetically related member of a previously identified family with FE
  • Ability of subject to understand and the willingness to sign a written document.

Exclusion criteria

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Any condition that the investigator feels put the subject at unacceptable risk for participation in the study
  • Pregnancy (in family members who do not have eosinophilia)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Family-based
Time perspective
Prospective
Enrollment
50 participants (estimated)

Groups and cohorts

  • Affected family members

    Family members with peripheral blood eosinophilia

  • Unaffected family members

    Family members without peripheral blood eosinophilia

07

What researchers measure

Primary outcomes

  1. To study the natural history of familial hypereosinophilia (FE)

    Development of eosinophilic end organ manifestations

    Time frame: 30 years

Secondary outcomes

  1. To determine the immunologic and molecular mechanisms responsible for eosinophilia, eosinophil activation, and pathogenesis of FE

    Description of immunologic features of FE; identification of genetic driver(s) of FE

    Time frame: 30 years

  2. To identify early clinical or laboratory markers of disease progression

    Identification of clinical or laboratory markers that become abnormal prior to disease progression in FE

    Time frame: 30 year

08

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · Contactccopr@nih.gov · 800-411-1222
09

References and documents

Publications

  • Rioux JD, Stone VA, Daly MJ, Cargill M, Green T, Nguyen H, Nutman T, Zimmerman PA, Tucker MA, Hudson T, Goldstein AM, Lander E, Lin AY. Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33. Am J Hum Genet. 1998 Oct;63(4):1086-94. doi: 10.1086/302053. PubMed 9758611 ↗
  • Prakash Babu S, Chen YK, Bonne-Annee S, Yang J, Maric I, Myers TG, Nutman TB, Klion AD. Dysregulation of interleukin 5 expression in familial eosinophilia. Allergy. 2017 Sep;72(9):1338-1345. doi: 10.1111/all.13146. Epub 2017 Apr 18. PubMed 28226398 ↗
  • Klion AD, Law MA, Riemenschneider W, McMaster ML, Brown MR, Horne M, Karp B, Robinson M, Sachdev V, Tucker E, Turner M, Nutman TB. Familial eosinophilia: a benign disorder? Blood. 2004 Jun 1;103(11):4050-5. doi: 10.1182/blood-2003-11-3850. Epub 2004 Feb 26. PubMed 14988154 ↗

Individual participant data

Plan to share: Undecided — This is a longitudinal observational study in a rare inherited disease. At this point in time, there is no plan to share individual participant data as the main outcomes of the study are based on group data (incidence of end organ manifestations in the group) and identification of genetic and immunologic drivers of familial eosinophilia.

10

Timeline

2 registry updates since Sep 25, 2026

Started Jun 2005 (actual).

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2004
First posted
Sep 20, 2004
StartActual
Jun 8, 2005
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: description
2 updates, last Oct 29, 2026
Show all 2 updates
  1. Oct 29, 2026
    Minor edits only
    + 1 other change: description
  2. Oct 27, 2026
    Minor edits only
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT00091871
Responsible party
Sponsor
First posted
Sep 20, 2004
Start date
Jun 8, 2005
Last update
Oct 29, 2026

Study contacts

Thomas W Brown, R.N.
Contact
browntw@mail.nih.gov
(301) 402-7823
Amy D Klion, M.D.
Contact
amy.klion@nih.gov
(240) 381-6073
Amy D Klion, M.D.
principal investigator · National Institute of Allergy and Infectious Diseases (NIAID)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion